NeoGenomics acquires Human Longevity’s oncology tech

Latest articles

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Click the globe for translations.

Acquisition of Human Longevity’s oncology division for $37m demonstrates both the opportunities and challenges for Longevity investing.

On Friday, NeoGenomics announced that it had agreed to purchase Human Longevity’s Oncology division for $37 million, in a deal financed by cash in hand [1]. The acquisition is the largest made by NeoGenomics since it bought Genoptix for $127 million in October 2018 [2].

Last year Human Longevity’s Oncology division generated in $10million in revenue and ended the year with $15 million in signed contracts [3]. In the short term at least, NeoGenomics believes the acquisition will be dilutive of their profits for 2020 before starting to generate dividends.

There have been signs of uncertainty around Human Longevity for some time. Back in November, we picked up on emerging issues at Human Longevity when they bridged $30 million deal with Emerging Technology Partners. After a cumulative investment of $330 million, the question has to be asked whether this represents sound ROI for investors?

It’s hard to say because Human Longevity’s communications are so opaque. In a statement, they describe their key areas as being diabetes, obesity, heart disease, liver disease and dementia, so it is possible that this disposal simply allows them to focus on other areas. However, it may also be the start of further disposals.

A summary of comments on the website Glassdoor in which current and former staff anonymously review companies highlights the challenges as well as opportunities.

On the positive side are comments such as these:

  • “With the current leadership, HLI has been more productive in the last six months than the company has ever been.”
  • “Although past business decisions have been frustrating, I would like to attribute that to HLI trying to be disruptive in the field.”

On the flip-side:

  • “The company is making new strides within Genetics/Genomics and as such runs into new hurdles that weren’t there the day before.”
  • “How do you expect to create a product with folks with lack of experience and knowledge are made in-charge of guiding product development.”

These comments highlight both the opportunities and challenges of Longevity investing in an emerging field. Whatever the truth of the matter at Human Longevity Inc, we wish the staff and management well.

[1] http://bit.ly/30l0FAP

[2] https://genoptix.com/neogenomics-completes-acquisition-of-genoptix-inc/

[3] https://eu.news-press.com/story/money/companies/2020/01/10/neogenomics-acquires-oncology-division-human-longevity-inc/4431269002/

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Apollo closes $180m for age-related disease innovations

Apollo Health Ventures fund will drive breakthrough innovations combating age-related diseases. Apollo Health Ventures has announced the final closing of its second venture fund to...

Aging in place: technologies to live long and independently

Our comprehensive market intelligence report provides a deep dive into the opportunities and challenges facing the aging in place industry – and explains why...

Longevica raises $2.5 million for open research platform

$2.5m in funding to support longevity research platform and study to accelerate the discovery of life extension mechanisms, launching in 2022. Longevica, a life science...

A global perspective on consumer longevity data

WHO head of aging and health to present at ARK event focused on the importance of data in the quest for improved longevity. Tomorrow is...

    Subscribe to our newsletter